Literature DB >> 33037700

Fast-acting γδ T-cell subpopulation and protective immunity against infections.

Ling Shen1, Dan Huang1, Arwa Qaqish1, James Frencher1, Rui Yang2, Hongbo Shen2, Zheng W Chen1.   

Abstract

Unique Vγ2Vδ2 (Vγ9Vδ2) T cells existing only in human and non-human primates, account for the majority of circulating γδ T cells in human adults. Vγ2Vδ2 T cells are the sole γδ T-cell subpopulation capable of recognizing the microbial (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) produced by selected pathogens during infections. Recent seminal studies in non-human primate models have demonstrated that the unique HMBPP-specific Vγ2Vδ2 T cells are fast-acting, multi-functional, and protective during infections. This article reviews the recent seminal observations of Vγ2Vδ2 T cells in protective mechanisms against tuberculosis and other infections.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HMBPP; macaques; phosphoantigen; tuberculosis; vaccine; γδ T cells

Year:  2020        PMID： 33037700     DOI： 10.1111/imr.12927

Source DB:  PubMed          Journal:  Immunol Rev        ISSN： 0105-2896            Impact factor:   12.988


  6 in total

1.  A CD4+CD161+ T-Cell Subset Present in Unexposed Humans, Not Tb Patients, Are Fast Acting Cells That Inhibit the Growth of Intracellular Mycobacteria Involving CD161 Pathway, Perforin, and IFN-γ/Autophagy.

Authors:  Rui Yang; Ying Peng; Jiang Pi; Yidian Liu; Enzhuo Yang; Xiaona Shen; Lan Yao; Ling Shen; Robert L Modlin; Hongbo Shen; Wei Sha; Zheng W Chen
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 8.786

Review 2.  The Contribution of Human Herpes Viruses to γδ T Cell Mobilisation in Co-Infections.

Authors:  Fanny Martini; Eric Champagne
Journal:  Viruses       Date:  2021-11-26       Impact factor: 5.048

3.  MIR337-3p Enhances Mycobacterial Pathogenicity Involving TLR4/MYD88 and STAT3 Signals, Impairing VDR Antimicrobial Response and Fast-Acting Immunity.

Authors:  Shanshan Liang; Guixian Huang; Tian Wu; Ying Peng; Xi Liu; Xuejiao Ji; Wei Sha; Feifei Wang; Ling Shen; Hongbo Shen
Journal:  Front Immunol       Date:  2021-11-29       Impact factor: 7.561

4.  Adjunctive Zoledronate + IL-2 administrations enhance anti-tuberculosis Vγ2Vδ2 T-effector populations, and improve treatment outcome of multidrug-resistant tuberculosis1.

Authors:  Hongbo Shen; Enzhuo Yang; Ming Guo; Rui Yang; Guixian Huang; Ying Peng; Wei Sha; Feifei Wang; Ling Shen
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

5.  Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T Cell.

Authors:  Rui Yang; Qing He; Hui Zhou; Cheng Gong; Xing Wang; Xingpan Song; Fang Luo; Yang Lei; Qian Ni; Zili Wang; Shasha Xu; Yan Xue; Man Zhang; Haimei Wen; Lijuan Fang; Liang Zeng; Yongxiang Yan; Jian Shi; Jing Zhang; Jizu Yi; Pengfei Zhou
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

6.  Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.

Authors:  Rui Yang; Susu Shen; Cheng Gong; Xin Wang; Fang Luo; Fengyan Luo; Yang Lei; Zili Wang; Shasha Xu; Qian Ni; Yan Xue; Zhen Fu; Liang Zeng; Lijuan Fang; Yongxiang Yan; Jing Zhang; Lu Gan; Jizu Yi; Pengfei Zhou
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.